PAREA

Mental health conditions cause more years of ill-health than cancer, diabetes & heart disease combined, yet innovation has stalled. Join us 4 November in Brussels & online for our hybrid event, exploring how Europe can go from lagging to leading in mental health innovation. parea.eu/events/nov4

The EMA’s updated guideline on depression treatment takes effect today, with a dedicated section on psychedelics. PAREA contributed >10 comments during consultation, many of which shaped the final text. See the revised guideline here: tinyurl.com/ema-gl

Pain Alliance Europe (PAE), has launched an important EU-wide survey exploring the links between chronic pain, mental health, and self-management. The findings will inform advocacy efforts and shape better policies for people living with chronic pain across Europe.

lnkd.in/dv2vd7CC

Buenos Aires will host LaPsyConf, an international conference on mental health, longevity, and well-being. Tadeusz Hawrot opens with Global Issues: Mental Health Indicators, Global Regulation, and Economic Impact. Get 10% off with code PAREA. Register: www.lapsyconf.com

On Oct 1 in Lisbon, following the @psypaleu.bsky.social General Assembly, PAREA will join EU at @champalimaudf.bsky.social stakeholders for a full-day symposium focused on the ethical, regulatory & clinical dimensions of psychedelic-assisted care. Learn more & register: tinyurl.com/8h2jnup

On this World Suicide Prevention Day, PAREA supports the call to change the narrative on suicide, moving from stigma and silence to openness, understanding, and support. Together, prevention is possible. @iaspinfo.bsky.social

We’re pleased to support the upcoming Borealis Psychedelic Science Summit, a two-day scientific conference taking place in Stockholm on September 26–27, as a Community Partner. Learn more and register here: borealissummit.com

The WHO just released two reports on mental health. They show more than 1B people live with a disorder, while governments’ spending has barely moved since 2017. Europe leads at $51.76 per person, the Americas just $6.86. Disorders keep rising, but investment hasn’t.
🔗 lnkd.in/dW_NU3VA

PAREA is partnering with Inawe Foundation for Psymposium Madrid 2025, Oct 2–4. The conference features leading experts in mental health, neuroscience, and psychedelics, and our community receives 10% off tickets with code PSYMP0S1UM2025. More here: tinyurl.com/parea-psympo...

The Dutch Medicines Evaluation Board will host a Pipeline Meeting on 5 Nov 2025, focusing on the regulatory development of psychedelics.

Pharmaceutical companies can apply to present and discuss psychedelic development challenges with Dutch regulators.
Deadline: 29 Aug tinyurl.com/meb-pipeline...

Norway just took a big step in mental health: its regulator will reimburse off-label generic IV ketamine for treatment-resistant depression paired with psychotherapy. Backed by a positive HTA, years of protocolized use, and NORAAD’s €2.2m study. First in Europe. More: tinyurl.com/norway-ketam...

PAREA has submitted its contribution to the EU’s EU4Health 2026 consultation. Our key message: mental health innovation must become a strategic and structural priority for EU health policy. The consultation is open until 30 September 2025. Our full contribution is available here: lnkd.in/dECfeG5d

PsyPal just enrolled its first patient in the EU’s first multi-site trial of psilocybin therapy for palliative care beyond cancer.
100+ patients, 4 sites, 1 historic step for mental health in Europe. Read the full press release here: tinyurl.com/psypal-augus...

Germany becomes the first EU country to approve compassionate use of psychedelic therapy. Patients who haven’t responded to conventional depression treatments can now access it at CIMH and the OVID Clinic. A major step toward broader access to psychedelic care in Europe! tinyurl.com/compassionat...

We’re happy to welcome Irish Doctors for Psychedelic Assisted Therapy as the newest member of PAREA’s Community Supporters network. This fall, PAREA will join the Psychedelic Research Conference, co-hosted by IDPAT and Trinity College Dublin. More here: tinyurl.com/idpat

Europe Invests in the Future of Psychedelic Science: INTEGRATE Doctoral Network Launches with €4.3 Million in Funding — PAREA A second major EU-funded project in psychedelic science, following PsyPal, will start in the coming months. INTEGRATE will be a doctoral training network supported by €4.3 million in EU funding throug...

Big news for psychedelic research in Europe:

The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments.

More here: parea.eu/parea-news/i...

New expert commentary outlines five priorities to advance psychedelic therapies in mental health care — PAREA A new expert commentary is outlining five priorities to advance psychedelic therapies in mental health care. Published on The Mental Elf—an online resource on mental health research— the piece follow...

A new expert commentary published on The Mental Elf outlines five priorities to advance psychedelic mental health care. Co-authored by leading voices across sectors, it reflects growing momentum. PAREA is pleased to have contributed input. Learn out more about it here: parea.eu/parea-news/i...

Big news: PAREA just received a €50K grant from Entheon Foundation to strengthen EU advocacy, push for more funding, and build capacity for psychedelic-assisted mental health treatments across Europe. Thanks to Entheon for backing this work!
Read more here: parea.eu/parea-news/e...

PAREA is delighted to welcome Nico Gusac to our team as our new Communications Officer!
With a multidisciplinary background and a deep commitment to mental health, culture, and ethics, Nico is passionate about healing as a relational and systemic process, convinced that community is medicine.

Today, the EU4Health Civil Society Alliance launched Health4Europe: a blueprint for the next EU Health Programme. As a proud member, PAREA endorses this call to keep health a top EU priority in the next MFF. Read the full proposal here: tinyurl.com/eu4healthblueprint

On February 26, 2025, during the Psychedelics as Medicine conference in Reykjavik, Iceland, representatives from all Nordic psychedelic associations signed the Manifesto for the Nordic Psychedelic Network Initiative. Learn more in our latest guest article by Cecilie Byholt Endresen: bit.ly/3TOXmyg

We’re proud to be representing the PsyPal project @psypaleu.bsky.social at Psychedelic Science, in Denver, and at the European Academy of Neurology Congress, in Helsinki!

Compass Pathways released topline data from the first-ever Phase 3 trial of a classical psychedelic - COMP360 psilocybin - for treatment-resistant depression: significant improvements and no new safety concerns. Attention now turns to the larger COMP006 trial.

PAREA is turning 3! 🎉

We’ve spent the past days in Denver at Psychedelic Science 2025 and now at the European Academy of Neurology @ean.org Congress in Helsinki connecting with peers and team members face-to-face.

Thanks to everyone who’s supported our journey — we’re just getting started.

🧠 One week until #EAN2025 in Helsinki!
We'll be there 21–24 June with a booth in the Neurohood + a session at the Scientific Theatre.

Come learn about the evolving frontier of psychedelic innovation in neurology, and about EU trial PsyPal (@psypaleu.bsky.social)! tinyurl.com/ean-session

PAREA will be at Psychedelic Science 25 next week, in Denver, Colorado!
🗓️Thursday, 4:30 PM “Progress in the EU: Lessons from Multi-Stakeholder Processes”
🗓️Friday, 2:45 PM “The Potential for PAT in Conflict-Affected Populations: Ukraine and the Balkanss”
For 15% off, use SPEAKER15: lnkd.in/dCQiuar9

PAREA submitted our consultation response on the EU Biotech Act, outlining recommendations to unlock mental health innovation:
• Support for early-stage biotechs
• Dedicated EU Mental Health Innovation Fund
• Pan-European trial infrastructure
🔗Full submission: ec.europa.eu/info/law/bet...

The EUDA released its European Drug Report, highlighting growing interest in psychedelics for therapeutic use. Research on psilocybin, MDMA, DMT, and LSD for PTSD and depression is advancing. New funding includes €6.5M for psychedelic therapy in palliative care. www.euda.europa.eu/publications...

🚨 Czech Parliament passes law allowing psilocybin therapy for depression, anxiety, and addiction in licensed clinical settings. This positions Czechia as a leader in responsible psychedelic use. PAREA applauds this evidence-based approach. Read more here: parea.myflodesk.com/ysbmi7ib6b

The WHO has issued a rapid communication on its forthcoming guideline on controlled medicines, on which PAREA participated as an external reviewer. tinyurl.com/who-gl-rc